Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | NNMT | P40261 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.41 |
| ▸ | FEN1 | P39748 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133539 | 1.00 | GRM5 (0.52) | GRM5NNMTALOX5APFEN1ALDH1A1 | |
| SCHEMBL21201865 | 0.91 | NNMT (0.47) | GRM5NNMTALOX5APFEN1ALDH1A1 | |
| SCHEMBL22227201 | 0.90 | NNMT (0.46) | GRM5NNMTALOX5APFEN1ALDH1A1 | |
| SCHEMBL14242971 | 0.86 | GRM5 (0.48) | GRM5NNMTALOX5APFEN1PIK3R1 | |
| SCHEMBL25787851 | 0.86 | NNMT (0.62) | GRM5NNMTALOX5APFEN1PIK3R1 | |
| SCHEMBL16865846 | 0.82 | GRM5 (0.45) | GRM5NNMTALOX5APFEN1POLB | |
| SCHEMBL15878795 | 0.82 | GRM5 (0.45) | GRM5NNMTALOX5APFEN1ALDH1A1 | |
| Bromide SCHEMBL16859042 | 0.81 | GRM5 (0.44) | GRM5NNMTALOX5APFEN1POLB | |
| SCHEMBL24099923 | 0.79 | FEN1 (0.43) | GRM5NNMTALOX5APFEN1PIK3R1 | |
| SCHEMBL22225994 | 0.79 | GRM5 (0.45) | GRM5NNMTALDH1A1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023129512-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| EP-3856178-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020145250-A1 | 15-PGDH INHIBITOR | 杏林製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2012167600-A1 | A HETEROCYCLIC [B]PYRIDONE COMPOUND, INTERMEDIATES THEREOF, METHOD OF PREPARATION AND USES | 上海汇伦生命科技有限公司 (CN) | 2012-12-13 | — | — | WO | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 153/4885NNMT 4068/4885ALOX5AP 508/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | GRM5 309/4885NNMT 4025/4885ALOX5AP 1017/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 153/4885NNMT 4068/4885ALOX5AP 508/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 153/4885NNMT 4068/4885ALOX5AP 508/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | GRM5 479/4885NNMT 1294/4885ALOX5AP 1864/4885 |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | MET, PDXK, FLT3 | GRM5 648/4885NNMT 593/4885ALOX5AP 1466/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GRM5 153/4885NNMT 4068/4885ALOX5AP 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.